Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases

Regulatory Peptides

Volumn 145, Issue 1-3, 2008, Pages 24-32

  Li, Min ^a   Maderdrut, Jerome L ^a   Lertora, Juan J L ^a   Arimura, Akira ^a   Batuman, Vecihi ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Diabetic nephropathy; Fibrosis; Gentamicin induced renal toxicity; Immunoglobulin light chains; Inflammation; Mitogen activated protein kinase; Myeloma kidney; PACAP; PACAP receptors

Indexed keywords

DEXAMETHASONE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P50; STRESS ACTIVATED PROTEIN KINASE; TAMM HORSFALL GLYCOPROTEIN;

DIABETIC NEPHROPATHY; DRUG HALF LIFE; DRUG POTENCY; ENDOCYTOSIS; ENZYME ACTIVATION; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY PROXIMAL TUBULE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; REVIEW;

ANIMALS; GENTAMICINS; HUMANS; KIDNEY DISEASES; MULTIPLE MYELOMA; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE;

ANIMALIA;

EID: 37349038785     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2007.09.012     Document Type: Review

References (79)

1. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., Culler M.D., and Coy D.H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164 (1989) 567-574
2. Miyata A., Jiang L., Dahl R.D., Kitada C., Kubo M., Fujono M., Minamino N., and Arimura A. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170 (1990) 643-648
3. Arimura A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn J Physiol 48 (1998) 301-331
4. Vaudry D., Gonzalez B.J., Basille M., Pamantung T.F., Fournier A., and Vaudry H. PACAP acts as a neurotrophic factor during histogenesis of the rat cerebellar cortex. Ann N Y Acad Sci 921 (2000) 293-299
5. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., and Waschek J.A. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50 (1998) 265-270
6. Segre G.V., and Goldring S.R. Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family. Trends Endocrinol Metab 4 (1993) 309-314
7. Delgado M., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kB-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem 276 (2001) 369-380
8. Ganea D., and Delgado M. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP. Arch Immunol Ther Exp (Warsz) 49 (2001) 101-110
9. Kyle R.A., Gertz M.A., Witzig T.E., Lust J.A., Lacy M.Q., Dispenzieri A., Fonseca R., Rajkumar S.V., Offord J.R., Larson D.R., Plevak M.E., Therneau T.M., and Greipp P.R. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78 (2003) 21-33
10. Abbott K.C., and Agodoa L.Y. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 56 (2001) 207-210
11. Iggo N., Winearls C.G., and Davies D.R. The development of cast nephropathy in multiple myeloma. QJM 90 (1997) 653-656
12. Haubitz M., and Peest D. Myeloma-new approaches to combined nephrological-haematological management. Nephrol Dial Transplant 21 (2006) 582-590
13. Herrera G.A., Joseph L., Gu X., Hough A., and Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 128 (2004) 875-879
14. Ivanyi B. Development of chronic renal failure in patients with multiple myeloma. Arch Pathol Lab Med 117 (1993) 837-840
15. Lin J., Markowitz G.S., Valeri A.M., Kambham N., Sherman W.H., Appel G.B., and D'Agati V.D. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 12 (2001) 1482-1492
16. Sanders P.W. A new twist in myeloma treatment. Blood 107 (2006) 413-414
17. Guan S., el-Dahr S., Dipp S., and Batuman V. Inhibition of Na-K-ATPase activity and gene expression by a myeloma light chain in proximal tubule cells. J Investig Med 47 (1999) 496-501
18. Pote A., Zwizinski C., Simon E.E., Meleg-Smith S., and Batuman V. Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells. Am J Kidney Dis 36 (2000) 735-744
19. Sengul S., Zwizinski C., and Batuman V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol 284 (2003) F1245-F1254
20. Sengul S., Zwizinski C., Simon E.E., Kapasi A., Singhal P.C., and Batuman V. Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int 62 (2002) 1977-1988
21. Arimura A., Li M., and Batuman V. Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38. Ann N Y Acad Sci 1070 (2006) 1-4
22. Arimura A., Li M., and Batuman V. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107 (2006) 661-668
23. Barrie A.P., Clohessy A.M., Buensuceso C.S., Rogers M.V., and Allen J.M. Pituitary adenylyl cyclase-activating peptide stimulates extracellular signal-regulated kinase 1 or 2 (ERK1/2) activity in a Ras-independent, mitogen-activated protein Kinase/ERK kinase 1 or 2-dependent manner in PC12 cells. J Biol Chem 272 (1997) 19666-19671
24. Douziech N., Lajas A., Coulombe Z., Calvo E., Laine J., and Morisset J. Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines. Endocrine 9 (1998) 171-183
25. Lelievre V., Pineau N., and Waschek J.A. The biological significance of PACAP and PACAP receptors in human tumors: from cell lines to cancers. In: Vaudry H., and Arimura A. (Eds). Pituitary adenylate cyclase-activating polypeptide (2003), Kluwer Academic Publishers, Dordrecht 361-399
26. Li M., Cortez S., Nakamachi T., Batuman V., and Arimura A. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells. Cancer Res 66 (2006) 8796-8803
27. Ritz E. Cast nephropathy in myeloma - does PACAP38, a new member of the vasoactive intestinal peptide family, open a therapeutic window?. J Am Soc Nephrol 17 (2006) 911-913
28. Risdon R.A., Sloper J.C., and De Wardener H.E. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 2 (1968) 363-366
29. Sharma K., Jin Y., Guo J., and Ziyadeh F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45 (1996) 522-530
30. Sharma K., and McGowan T.A. TGF-b in diabetic kidney disease: role of novel signaling pathways. Cytokine Growth Factor Rev 11 (2000) 115-123
31. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., and Border W.A. Expression of transforming growth factor b is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 90 (1993) 1814-1818
32. Nagai J., and Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 19 (2004) 159-170
33. Leung J.C., Marphis T., Craver R.D., and Silverstein D.M. Altered NMDA receptor expression in renal toxicity: Protection with a receptor antagonist. Kidney Int 66 (2004) 167-176
34. Pedraza-Chaverri J., Barrera D., Maldonado P.D., Chirino Y.I., Macias-Ruvalcaba N.A., Medina-Campos O.N., Castro L., Salcedo M.I., and Hernandez-Pando R. S-allylmercaptocysteine scavenges hydroxyl radical and singlet oxygen in vitro and attenuates gentamicin-induced oxidative and nitrosative stress and renal damage in vivo. BMC Clin Pharm 4 (2004) 5 [electronic resource]
35. Reglodi D., Somogyvari-Vigh A., Vigh S., Kozicz T., and Arimura A. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 31 (2000) 1411-1417
36. Reglodi D., Somogyvari-Vigh A., Vigh S., Maderdrut J.L., and Arimura A. Neuroprotective effects of PACAP38 in a rat model of transient focal ischemia under various experimental conditions. Ann N Y Acad Sci 921 (2000) 119-128
37. Banks W.A., Kastin A.J., Komaki G., and Arimura A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther 267 (1993) 690-696
38. Delgado M., Munoz-Elias E.J., Martinez C., Gomariz R.P., and Ganea D. VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines. Ann N Y Acad Sci 897 (1999) 401-414
39. Chiodera P., Volpi R., Capretti L., Caffarri G., Magotti M.G., and Coiro V. Effects of intravenously infused pituitary adenylate cyclase-activating polypeptide on adenohypophyseal hormone secretion in normal men. Neuroendocrinology 64 (1996) 242-246
40. Delgado M., Leceta J., Abad C., Martinez C., Ganea D., and Gomariz R.P. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Neuroimmunol 99 (1999) 61-71
41. Abad C., Martinez C., Leceta J., Gomariz R.P., and Delgado M. Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol 167 (2001) 3182-3189
42. Linden A., Cardell L.O., Yoshihara S., and Nadel J.A. Bronchodilation by pituitary adenylate cyclase-activating peptide and related peptides. Eur Respir J 14 (1999) 443-451
43. Abad C., Martinez C., Juarranz M.G., Arranz A., Leceta J., Delgado M., and Gomariz R.P. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124 (2003) 961-971
44. Belai A., Boulos P.B., Robson T., and Burnstock G. Neurochemical coding in the small intestine of patients with Crohn's disease. Gut 40 (1997) 767-774
45. Dorfmuller P., Perros F., Balabanian K., and Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 22 (2003) 358-363
46. Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., Funk G.C., Hamilton G., Novotny C., Burian B., and Block L.H. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111 (2003) 1339-1346
47. Keegan B.M., and Noseworthy J.H. Multiple sclerosis. Annu Rev Med 53 (2002) 285-302
48. Kato H., Ito A., Kawanokuchi J., Jin S., Mizuno T., Ojika K., Ueda R., and Suzumura A. Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells. Mult Scler 10 (2004) 651-659
49. Holz G.G., and Chepurny O.G. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 10 (2003) 2471-2483
50. Jamen F., Persson K., Bertrand G., Rodriguez-Henche N., Puech R., Bockaert J., Ahren B., and Brabet P. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invest 105 (2000) 1307-1315
51. Yada T., Sakurada M., Ihida K., Nakata M., Murata F., Arimura A., and Kikuchi M. Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. J Biol Chem 269 (1994) 1290-1293
52. Filipsson K., Tornoe K., Holst J., and Ahren B. Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans. J Clin Endocrinol Metab 82 (1997) 3093-3098
53. Ganea D., and Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med 13 (2002) 229-237
54. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., and Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52 (2000) 269-324
55. Sherwood N.M., Krueckl S.L., and McRory J.E. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocrine Rev 21 (2000) 619-670
56. Frohman L.A., Downs T.R., Williams T.C., Heimer E.P., Pan Y.C., and Felix A.M. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest 78 (1986) 906-913
57. Kieffer T.J., McIntosh C.H., and Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995) 3585-3596
58. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214 (1993) 829-835
59. Sawano S., Ohashi S., Masuda H., and Ozaki S. Degradation and bioactivities of human growth hormone releasing factor-(1-29)-amide (GRF-29) and its related peptides. Endocrine Society (70th annual meeting), New Orleans, Louisiana (1988) 86 (Abstract)
60. Zhu L., Tamvakopoulos C., Xie D., Dragovic J., Shen X., Fenyk-Melody J.E., Schmidt K., Bagchi A., Griffin P.R., Thornberry N.A., and Sinha Roy R. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 278 (2003) 22418-22423
61. Uchida D., Arimura A., Somogyvari-Vigh A., Shioda S., and Banks W.A. Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res 736 (1996) 280-286
62. Flotte T.R., Afione S.A., Conrad C., McGrath S.A., Solow R., Oka H., Zeitlin P.L., Guggino W.B., and Carter B.J. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A 90 (1993) 10613-10617
63. Nakai H., Herzog R.W., Hagstrom J.N., Walter J., Kung S.H., Yang E.Y., Tai S.J., Iwaki Y., Kurtzman G.J., Fisher K.J., Colosi P., Couto L.B., and High K.A. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 91 (1998) 4600-4607
64. Kaplitt M.G., Leone P., Samulski R.J., Xiao X., Pfaff D.W., O'Malley K.L., and During M.J. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8 (1994) 148-154
65. Zolotukhin S., Potter M., Hauswirth W.W., Guy J., and Muzyczka N. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70 (1996) 4646-4654
66. Kessler P.D., Podsakoff G.M., Chen X., McQuiston S.A., Colosi P.C., Matelis L.A., Kurtzman G.J., and Byrne B.J. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A 93 (1996) 14082-14087
67. Xiao W., Chirmule N., Berta S.C., McCullough B., Gao G., and Wilson J.M. Gene therapy vectors based on adeno-associated virus type 1. J Virol 73 (1999) 3994-4003
68. Fisher K.J., Gao G.P., Weitzman M.D., DeMatteo R., Burda J.F., and Wilson J.M. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 70 (1996) 520-532
69. Amiss T.J., and Samulski R.J. Methods for adeno-associated virus-mediated gene transfer into muscle. Method Mol Biol 175 (2001) 455-469
70. Yoshida M., Iwasaki Y., Asai M., Nigawara T., and Oiso Y. Gene therapy for central diabetes insipidus: effective antidiuresis by muscle-targeted gene transfer. Endocrinology 145 (2004) 261-268
71. High K.A. Adeno-associated virus-mediated gene transfer for hemophilia B. Int J Hematol 76 (2002) 310-318
72. Murphy J.E., Zhou S., Giese K., Williams L.T., Escobedo J.A., and Dwarki V.J. Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. Proc Natl Acad Sci U S A 94 (1997) 13921-13926
73. Bohl D., Bosch A., Cardona A., Salvetti A., and Heard J.M. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle. Blood 95 (2000) 2793-2798
74. Manno C.S., Chew A.J., Hutchison S., Larson P.J., Herzog R.W., Arruda V.R., Tai S.J., Ragni M.V., Thompson A., Ozelo M., Couto L.B., Leonard D.G., Johnson F.A., McClelland A., Scallan C., Skarsgard E., Flake A.W., Kay M.A., High K.A., and Glader B. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101 (2003) 2963-2972
75. Leceta J., Gomariz R.P., Martinez C., Abad C., Ganea D., and Delgado M. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann N Y Acad Sci 921 (2000) 92-102
76. Wang H.Y., Jiang X.M., and Ganea D. The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells. J Neuroimmunol 104 (2000) 68-78
77. Delgado M., and Ganea D. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol 167 (2001) 966-975
78. Martinez C., Abad C., Delgado M., Arranz A., Juarranz M.G., Rodriguez-Henche N., Brabet P., Leceta J., and Gomariz R.P. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A 99 (2002) 1053-1058
79. Pozo D., Guerrero J.M., and Calvo J.R. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit LPS-stimulated MIP-1a production and mRNA expression. Cytokine 18 (2002) 35-42